News

  • The motif, made up of 10 segments, enables participants to track 10 Covid-related symptoms: fatigue and muscle ache, nausea, dry cough, shortness of breath, fever, loss of taste/smell, runny nose, sore throat, diarrhoea, and headache. As well as tracking symptoms the app includes medication adherence questions so the doctors can keep track of which participants use the sinus rinse and mouth wash. In addition to the remote data capture the trial onboarding and instructions also needed to be virtual. Dr Khan and his team produced a Youtube video to educate and guide people through the necessary steps. Although a small team, they have demonstrated what can be achieved when starting a trial using a virtual and digitised design. The trial is due to run through August 2020 and the team are already seeing early signs of success. Results for patients, who have a low viral load, using both treatments have eradicated the virus within 48 hours. Hopefully this trial will open the door to preventing the transmission of Covid-19

    uMotif support NHS study in the fight against Covid-19

    Read More

  • uMotif raise £5 million to power decentralised clinical trials and get therapies to patients faster

    Read More

  • uMotif recognised as one of BusinessCloud’s top 100 Healthtech Pioneers

    Read More
  • On-Demand Webinar

    On-Demand Webinar: Reimagining clinical trials following Covid-19 disruption

    Read More
  • Artificial Intelligence

    Informa Connect Industry Voices – Will Artificial Intelligence revolutionise clinical trials?

    Read More
  • Hypo-RESOLVE study

    Patient-Centric eClinical Platform Powers Virtual Data Capture in European Hypoglycaemia Study

    Read More
  • The Spencer Group Podcast 31

    The Spencer Group Podcast: How Covid-19 is accelerating the digitisation of research

    Read More
  • Pedestrians cross K Street in Northwest Washington on a rainy day in October 2018 by Robert Miller for The Washington Post

    No Rain, No Pain: Study Links Foul Weather With Body Aches

    Read More

  • Medical Futurist Interview: Our CEO talks to Barts and the London MedTech Society about the impact of Covid-19

    Read More